- Global Pharma News & Resources

Outlook on the Pharmaceutical Analytical Testing Outsourcing Global Market to 2027 - Increasing focus on Regulation, Safety and Quality is Driving Growth -

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Analytical Testing Outsourcing Market- Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)" report has been added to's offering.

The Pharmaceutical Analytical Testing Outsourcing Market is expected to register a CAGR of 8.7% during the forecast period, 2022-2027.

Companies Mentioned

  • SGS SA
  • Labcorp (Toxikon, Inc)
  • Eurofins Scientific
  • Pace Analytical Services, Inc.
  • Intertek Group Plc
  • Thermo Fisher Scientific (Pharmaceutical Product Development, LLC )
  • WuXi AppTec
  • Boston Analytical
  • Charles River Laboratories International, Inc
  • West Pharmaceutical Services Inc.
  • Element Group (Exova Group PLC)
  • Merck KGaA

Key Market Trends

Pharmaceutical and Biopharmaceutical Companies Segment is Expected to Garner a Major Share During the Forecast Period.

By end user, the pharmaceutical and biopharmaceutical companies segment is expected to hold a significant share in the market studied over the forecast period. Factors such as rise in product development activities, growing research and development expenditures by the companies, and the need to develop novel therapies, among others, are expected to drive the growth of this segment.

In addition, rising mergers and acquisitions among the key market players are further expected to drive the growth of this segment studied. For instance, in February 2022, Personal Genome Diagnostics Inc. (PGDx), a key player in cancer genomics with a range of complete liquid biopsy and tissue-based solutions, was acquired by Labcorp. PGDx's technology complements and accelerates Labcorp's current liquid biopsy capabilities, as well as expands Labcorp's leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities. This puts Labcorp at the forefront of improving patient outcomes in oncology.

Furthermore, in December 2021, Eurofins Scientific entered into a share purchase agreement with Transgenic Inc. to acquire Genetic Lab Co., Ltd., a molecular biology-based testing provider for diagnostics, biomarker development, and drug discovery. With this acquisition, the Eurofins network will further strengthen its position in the Japanese market by extending its service offering in biopharmaceutical services and clinical testing in Japan.

Therefore, owing to the above-mentioned factors, the segment is expected to witness significant growth over the forecast period.

North America Holds a Major Share and Expected to do Same in the Forecast Period

North America holds a major share in the pharmaceutical analytical testing outsourcing market during the forecast period.

The factors contributing to the growth of this region include advancements in technologies, the strong foothold of key market players, the rise in chronic cases, and the rise in pharmaceutical research and development and funding, among others. For instance, in October 2021, Pace Analytical Services, LLC acquired Velesco Pharmaceutical Services, Inc. Velesco, is a CDMO that specializes in liquid, semi-solid, and oral solid dose product development. This acquisition adds significant experience and expertise in the development of liquid, semi-solid, and oral solid dose products for pre-clinical and clinical use, allowing Pace to support a growing number of clients throughout the drug development process.

In addition, in July 2021, Pace Analytical Services acquired Drug Delivery Experts, LLC (DDE). DDE, also a CDMO, specializes in complex injectable drug formulations and combination drug-device product development. As a result of the acquisition, Pace will be able to assist a growing number of clients that require services throughout the drug development process, as well as contribute experience in drug-device combo products and extended-release injectable technologies. Such developments in the United States will lead to increased adoption of pharmaceutical analytical testing outsourcing services in this region, thereby, driving the market growth.

Furthermore, a rise in research funding for clinical trials and supportive activities in the United States is also expected to contribute to the market growth over the forecast period. For instance, according to the National Institute of Health (NIH) data published in June 2021, the funding in the United States for clinical trials and supportive activities for 2018, 2019, and 2020 was USD 5,207 million, USD 6,058 million, and USD 6,637 million, respectively. Therefore, the rise in research funding for such activities will lead to increased adoption of pharmaceutical analytical testing outsourcing services, driving regional market growth.

Key Topics Covered:


1.1 Study Assumptions and Market Definition

1.2 Scope of the Study




4.1 Market Overview

4.2 Market Drivers

4.2.1 Increasing focus on Regulation, Safety and Quality

4.2.2 Pricing Benefits of Outsourcing

4.2.3 Rise in the Demand for Biosimilars and Biopharmaceutical Products as well as for Analytical Drugs

4.3 Market Restraints

4.3.1 Increase in the Concerns Regarding Privacy/Theft of Confidential Data of Manufacturing Pharmaceuticals

4.3.2 Varied Outsourcing Expenditures by Companies

4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION (Market size in USD million)

5.1 By Services

5.2 By End User

5.3 Geography


6.1 Company Profiles


For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 12-Jul-2022